Soluble PD-L1 Is a Predictive and Prognostic Biomarker in Advanced Cancer Patients Who Receive Immune Checkpoint Blockade Treatment

0
227
Researchers investigated the significance of sPD-L1 in cancer patients receiving immune checkpoint inhibitor therapy.
[Scientific Reports]
Full Article